522 results about "Therapy HIV" patented technology

This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.

The invention encompasses pharmaceutical compositions and methods for using Compound 1 in combination with other agents for treating patients with AIDS or HIV infection.

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS. The compounds of the invention for the general Formula I: wherein: Z is Q is selected from the group consisting of: -W- is

There is provided inter alia use of 2′,3′-dideoxy-3′-hydroxymethylcytosine or a prodrug or salt thereof in the manufacture of a medicament for the treatment of HIV infection wherein the reverse transcriptase of the HIV bears at least one mutation that allows an obligate chain terminating nucleoside- or nucleotide phosphate to be excised from the nascent DNA strand by ATP- or pyrophosphate-mediated excision.

The invention provides a completely oral medicament for treating acquired immune deficiency syndrome (AIDS), comprising the following components: hedyotis diffusa, honeysuckle, meadowrueleaf corydalis root, dandelion, weeping forsythia, asparagus, ophiopogon root, figwort root, fresh rehmannia root, peach kernel, chuanxiong rhizome, zedoary, achyranthes root, dahurian patrinia herb, giant knotweed, stiff silkworm, isatis root, white peony root, polygonatum, bitter caramon, mistletoe, tortoise plastron, glossy privet fruit, oyster, pollen, salvia miltiorrhiza, tree peony bark, bupleurum, bitter orange, cimicifuga foetida, dried orange peel, amomum fruit, officinal magnolia bark, rose, songaria cynomorium herb, self-heal, medicine terminalia fruit, gromwell, licorice, chrysanthemum, castor bean, bullfrog gallbladder, baikal skullcap root, medicated leaven, malt, rice sprout, chicken's gizzard-skin, radish seed, scorch-fried crataegus, Chinese yam, astragalus root, bighead atractylodes rhizome, sealwort, dangshen, prepared rehmannia root, cornus fruit, tuckahoe, jujube, Chinese wolfberry, cistanche, dragon bone, oyster, epimedium, curculigo root, deerhorn glue, ginseng, donkey-hide glue, white fungus, angelica, spatholobus stem and turtle shell. The medicament provided by the invention not only can cure AIDS and has good therapeutic effect on AIDS, but also can prevent infection of AIDS.

The present invention relates to pharmaceutical preparations and methods for treating individuals infected with the human immunodeficiency virus (HIV). The pharmaceutical preparations comprise an immunomodulating agent and a anti-retroviral compound. The pharmaceutical preparations are used to treat HIV infected patients, particularly for gastrointestinal complications arising from viral infection. In addition, the pharmaceutical preparations of the present invention have the effect of raising the levels of CD4⁺ single positive and CD4⁺ and CD8⁺ double positive T cells, thus promoting restoration and normalization of the immune system following HIV infection.

The invention relates to the use of pramipexole and the pharmacologically acceptable acid addition salts thereof as well as hydrates and solvates thereof, for preparing a pharmaceutical composition for the prevention and/or treatment of HIV encephalopathy.

The invention discloses low molecular weight carboxyl-reduced derivatives of fucosylated glycosaminoglycans (LCRG). The extent of carboxyl reduction is not less than 20%. Weight-average molecular weight of the LCRG is about 3000-20000Da, and monosaccharides comprise acetyl galactosamine (GalNAc), glucose (Glc) or glucuronic acid (GlcUA) and fucose (Fuc) or sulfates of fucose (shown as -OSO3-). The mole ratio of GalNAc, Glc (containing GlcUA), Fuc and -OSO3- is about 1: (1+-0.3): (1+-0.3): (3.0+-1.0). The LCRG is a potent human immunodeficiency virus (HIV) Type 1 entry inhibitor which acts on conserved regions and has the advantages of high activity against HIV Type 1, high therapeutic index and no-drug-resistance, and the LCRG can be used for preventing or curing HIV. The invention further provides a preparation method of the LCRG. The carboxyl-reduced derivatives of fucosylated glycosaminoglycans and medicinal compositions of the carboxyl-reduced derivatives can be prepared into injection agents, lyophilized powder or suppository and the like.

The invention belongs to the field of antivirus in medical chemistry, and relates to preparation of non-cyclic nucleotide phosphoamides and salts thereof and application of the non-cyclic nucleotide phosphoamides and salts thereof in treating human immunodeficiency virus (HIV), hepatitis B, hepatitis B virus (HBV) and other virus infection diseases. The non-cyclic nucleotide phosphoamides, and isomers, pharmaceutically acceptable salts, hydrates, solvates or crystals thereof have the general formula I of which the structure is disclosed in the specification. The invention also provides a pharmaceutical composition containing the compounds and isomers, pharmaceutically acceptable salts, hydrates, solvates or crystals thereof, and application of the compounds or composition in treating and/or preventing HIV and HBV infection. The compounds provided by the invention have the advantages of favorable anti-HIV and HBV activities, low oral dosage and low toxicity.

This invention involves a new treatment for AIDS recombinant expression vector, a modified cells (especially hematopoietic stem cells), and methods. The invention provides recombinant expression vector and modified cells (especially hematopoietic stem cells), its expression: (1) MGMT (P140K) gene; and (2) various (especially targeting HIV) siRNA and / or miRNAs and / or ribozymes, and / or anti - oligonucleotides. The invention also provides treatment of HIV infection, including (1) Preparation of the cell of this invention, then transplant to their patients with HIV infection; and (2) BG/BCNU appropriate treatment.

The invention discloses a low molecular weight glycosylated chondroitin sulfate, whose weight average molecular weight is 3000-15000Da. The monosaccharide composition comprises acetyl galactosamine (D-GalNAc), glucuronic acid (D-GlcUA), fucose (L-Fuc), or its sulfuric ester (expressed in -OS03<->), wherein the mole ratio of D-GalNAc to D-GlcUA to L-Fuc to -OS03<-> is 1: (1+/-0.3): (1+/-0.3): (3.5+/-0.5). The low molecular weight glycosylated chondroitin sulfate has a strong anti-HIV-1 virus activity, is a gp120 entry inhibitor, and can be used for preventing and/or treating AIDS. The invention also provides a method for preparing the low molecular weight glycosylated chondroitin sulfate and its composition preparation. Glycosylated chondroitin sulfate is depolymerized by the peroxide method to obtain a low molecular weight product, and then low molecular and/or high-molecular impurities of the product are removed by gel separation or ultrafiltration method. The low molecular weight glycosylated chondroitin sulfate and its medicinal composition can be prepared in the form of an injection, a lyophilized powder or a suppository.

The invention discloses a group of tenofovir disoproxil compounds with activity for inhibiting HIV-1/HBV virus replication and pharmaceutically acceptable salts thereof, and a preparation method and pharmaceutical applications thereof. The group of the compounds have a general formula I, wherein X=H, Y=H, R1=-CH2(CH2)mCH2O(CH2)nCH3, m=0-4, n=10-20, and R2, R3 and R4 are respectively described in the specification. The invention also discloses a pharmaceutical composition containing the group of the compounds. Experiments show that one of the compounds has the advantages that an activity for inhibiting HIV-1 virus replication is 20 times that of a positive control medicine zidovudine (AZT), 1,000 times that of TDF that is the best medicine for treating Aids and about 9 times that of CMX157 in a clinical stage, and lipid solubility is about 2 times that of CMX157. Experiments also show that the compounds provided by the invention have the activity for inhibiting HBV virus replication, and can be used for development of drugs for treating the Aids and hepatitis B.

GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a -GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.

The present invention discloses a medicine for resisting virus, raising immunity of human body and curing AIDS. Said medicine is a pure Chinese medicine preparation, and is made up by using 37 Chinese medicinal materials of licorice, radix trichosanthis, salvia root, dandelion herb, scutellaria root, coptis, phellodendron bark and others.

There are provided multimeric fusion proteins exhibiting anti-viral activity. The fusion proteins comprise the HR2 region of the ectodomain of the human immunodeficiency virus gp41 protein which is fused to a multimerisation domain peptide such as a trimerisation domain derived from tetranectin. The multimerised fusion proteins may be used as HIV fusion inhibitors in the treatment of AIDS.

A Chinese medicine in the form of decoction, tincture, powder, capsule, or pill for softening blood vessel, improving immunity and treating the diseases caused by virus, chlamydia, or mycoplasma, such as AIDS and SARS is disclosed. Its advantages are high curative effect, broad spectrum and no toxic by-effect.

This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.